IN2012DN06587A - - Google Patents

Info

Publication number
IN2012DN06587A
IN2012DN06587A IN6587DEN2012A IN2012DN06587A IN 2012DN06587 A IN2012DN06587 A IN 2012DN06587A IN 6587DEN2012 A IN6587DEN2012 A IN 6587DEN2012A IN 2012DN06587 A IN2012DN06587 A IN 2012DN06587A
Authority
IN
India
Prior art keywords
prophylaxis
compositions
treatment
equal
pharmaceutically acceptable
Prior art date
Application number
Inventor
Jatin Patel
Charles Frost
Jingpin Jia
Varapu Chandra Vema
Original Assignee
Bristol Myers Squibb Co
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06587(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Pfizer filed Critical Bristol Myers Squibb Co
Publication of IN2012DN06587A publication Critical patent/IN2012DN06587A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions comprising crystalline apixaban particles having a D equal to or less than 89 µm and a pharmaceutically acceptable carrier are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
IN6587DEN2012 2010-02-25 2011-02-24 IN2012DN06587A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30805610P 2010-02-25 2010-02-25
PCT/US2011/025994 WO2011106478A2 (en) 2010-02-25 2011-02-24 Apixaban formulations

Publications (1)

Publication Number Publication Date
IN2012DN06587A true IN2012DN06587A (en) 2015-10-23

Family

ID=43901603

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6587DEN2012 IN2012DN06587A (en) 2010-02-25 2011-02-24

Country Status (31)

Country Link
US (5) US9326945B2 (en)
EP (7) EP3257500B1 (en)
JP (4) JP5846647B2 (en)
KR (4) KR20170126016A (en)
CN (3) CN109602716A (en)
AU (1) AU2011220775B2 (en)
BR (1) BR112012021337A8 (en)
CA (1) CA2791171C (en)
CO (1) CO6640207A2 (en)
CY (5) CY1117434T1 (en)
DK (5) DK3251660T3 (en)
ES (5) ES2757603T3 (en)
HK (2) HK1243947B (en)
HR (5) HRP20160179T1 (en)
HU (4) HUE043932T2 (en)
IL (3) IL309564A (en)
IN (1) IN2012DN06587A (en)
LT (4) LT3017811T (en)
MX (3) MX353145B (en)
NZ (1) NZ601738A (en)
PE (3) PE20160042A1 (en)
PL (5) PL3246021T3 (en)
PT (5) PT3257500T (en)
RS (5) RS59810B1 (en)
RU (1) RU2685724C2 (en)
SG (2) SG10201501349VA (en)
SI (5) SI3017811T1 (en)
SM (5) SMT202000034T1 (en)
TR (1) TR201903195T4 (en)
WO (1) WO2011106478A2 (en)
ZA (1) ZA201205807B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201501349VA (en) 2010-02-25 2015-04-29 Bristol Myers Squibb Co Apixaban formulations
WO2013164839A2 (en) * 2012-03-06 2013-11-07 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
US20150272891A1 (en) * 2012-05-24 2015-10-01 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
MY179191A (en) * 2012-09-26 2020-10-30 Pfizer Apixaban liquid formulations
CN102908324A (en) * 2012-10-31 2013-02-06 南京正科制药有限公司 Apixaban tablet
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
CZ2013305A3 (en) 2013-04-23 2014-11-05 Zentiva, K.S. Novel crystalline forms of APIXABAN and process of their preparation
US20160113912A1 (en) * 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (en) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 Medicine preparation containing apixaban and preparation method of medicine preparation
EA202191301A1 (en) 2014-07-25 2021-11-30 Новартис Аг COMPOSITION OF TABLETS 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YLMETHYL) IMIDAZO [1,2-b] [1,2,4] TRIAZIN-2-YL] BENZAMIDE
CN104316637B (en) * 2014-10-30 2016-08-17 江苏宝众宝达药业有限公司 High effective liquid chromatography for measuring Eliquis cleans residual quantity
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
WO2016181276A1 (en) * 2015-05-08 2016-11-17 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
EP3380083A1 (en) 2015-11-26 2018-10-03 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106913528A (en) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 Eliquis micropill and preparation method thereof
US10537524B2 (en) 2016-01-12 2020-01-21 North & South Brother Pharmacy Investment Company Limited Apixaban solid composition and preparation method thereof
EP3195860A1 (en) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Method for producing an apixaban granulate
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (en) * 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 Apixaban tablet and preparation method thereof
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
RU2725153C1 (en) * 2016-09-24 2020-06-30 Кбп Биосаенсес Ко., Лтд Pharmaceutical composition containing mineralocorticoid receptor antagonist, and application thereof
CN106420651B (en) * 2016-09-28 2019-03-08 乐普药业股份有限公司 A kind of preparation method of Apixaban tablet
US11510909B2 (en) 2017-02-17 2022-11-29 Unichem Laboratories Ltd. Pharmaceutical composition of apixaban
JP7044115B2 (en) 2017-11-27 2022-03-30 三菱ケミカル株式会社 A resin modification composition for a thermoplastic resin containing a rubber-containing graft polymer composition, a rubber-containing graft polymer-containing resin composition and a molded product thereof.
KR20190075566A (en) 2017-12-21 2019-07-01 전자부품연구원 Monitoring system and method for using a multi-sensor
TR201722523A2 (en) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING APIXABAN
CN108236604A (en) * 2018-02-07 2018-07-03 中国药科大学 Eliquis flexible lipidosome
AU2019255599B2 (en) 2018-04-16 2024-02-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
KR20190130411A (en) 2018-05-14 2019-11-22 신일제약주식회사 Pharmaceutical formulation comprising apixaban and method for preparing the same
AU2019322287A1 (en) 2018-08-14 2021-03-11 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN111377915B (en) * 2018-12-30 2023-10-24 鲁南制药集团股份有限公司 Pyrazolo-pyridone compound crystal form D
CN109464415B (en) * 2019-01-09 2021-08-17 常州恒邦药业有限公司 Apixaban pharmaceutical composition and preparation method thereof
WO2021095048A1 (en) 2019-11-13 2021-05-20 Unison Pharmaceuticals Pvt. Ltd. Orally disintegrating pharmaceutical compositions of apixaban
CN111214442B (en) * 2020-02-13 2021-12-10 山东百诺医药股份有限公司 Apixaban co-micropowder
CN111494326A (en) * 2020-04-11 2020-08-07 南京正大天晴制药有限公司 Apixaban tablet and preparation method thereof
EP4251271A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A.S. DIRECT COMPRESSION PROCESS FOR NON-MICRONIZED APIXABAN FORMULATIONS
EP4251155A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A.S. Improved wet granulation processes for apixaban comprising formulations
TR202100250A2 (en) 2021-01-08 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi FILM COATED TABLET WITH APIKSABAN
WO2022150030A2 (en) 2021-01-08 2022-07-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet of apixaban
JP2022112698A (en) * 2021-01-22 2022-08-03 東和薬品株式会社 Pharmaceutical composition containing apixaban
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
CN117440807A (en) * 2021-06-08 2024-01-23 泰合生技药品股份有限公司 Apixaban membrane products and their uses
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method
JP2024057549A (en) * 2022-10-12 2024-04-24 日本ジェネリック株式会社 Tablets containing apixaban
KR102760108B1 (en) 2024-04-09 2025-01-24 에바바이오 주식회사 Enhanced bioavailability of amorphous Apixaban solid dispersion formulation by improving solubility and permeability and extended-release tablet thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
JP2002533465A (en) 1998-12-23 2002-10-08 デュポン ファーマシューティカルズ カンパニー Heterobicycles containing nitrogen as factor Xa inhibitors
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1427415B1 (en) * 2001-09-21 2009-08-12 Brystol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
DE10355461A1 (en) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
US7434502B2 (en) 2004-07-21 2008-10-14 Husqvarna Outdoor Products Inc. Bar knob with cam-operated locking mechanism
US20060016084A1 (en) * 2004-07-24 2006-01-26 Ching-Lin Liao Laser-Based datum instrument
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
WO2007053904A1 (en) 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
TW200824723A (en) * 2006-09-12 2008-06-16 Glaxo Group Ltd Pharmaceutical composition
FI20080351A0 (en) * 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with low drug content
CN101686959B (en) * 2007-05-02 2014-05-07 波托拉医药品公司 Combination therapy with a compound acting as a platelet ADP receptor inhibitor
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2723409C (en) * 2008-05-09 2016-11-08 Atacama Labs Oy Method and apparatus for dry granulation
KR20110043655A (en) 2008-07-11 2011-04-27 바스프 에스이 Amphiphilic Proteins as Morphology Modifiers
US20100018486A1 (en) * 2008-07-22 2010-01-28 Hung-Tao Liu Cathode energy fuel-saving device
EP4008327A1 (en) * 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SMT202000093T1 (en) * 2009-06-16 2020-03-13 Pfizer Dosage forms of apixaban
SG10201501349VA (en) 2010-02-25 2015-04-29 Bristol Myers Squibb Co Apixaban formulations
JP6092629B2 (en) * 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ Suspension prepared for use with rifaximin

Also Published As

Publication number Publication date
EP3251660B1 (en) 2019-10-16
RS59576B1 (en) 2019-12-31
PT3251660T (en) 2019-12-02
KR20230149861A (en) 2023-10-27
SMT201900649T1 (en) 2020-01-14
ES2757603T3 (en) 2020-04-29
WO2011106478A2 (en) 2011-09-01
SI3246021T1 (en) 2020-03-31
PT3246021T (en) 2020-02-21
CY1122384T1 (en) 2021-01-27
SMT201900212T1 (en) 2019-05-10
JP6033945B2 (en) 2016-11-30
CN102770126A (en) 2012-11-07
PT3017811T (en) 2019-03-21
AU2011220775A1 (en) 2012-09-13
RS58699B1 (en) 2019-06-28
EP3662899A1 (en) 2020-06-10
DK3017811T3 (en) 2019-04-01
LT3251660T (en) 2019-12-10
PE20160042A1 (en) 2016-01-28
EP2538925B1 (en) 2015-12-16
ES2562279T3 (en) 2016-03-03
IL221064A0 (en) 2012-09-24
HRP20160179T1 (en) 2016-04-08
JP2013521226A (en) 2013-06-10
NZ601738A (en) 2014-02-28
US20200375968A1 (en) 2020-12-03
RU2012140690A (en) 2014-03-27
EP3251660A1 (en) 2017-12-06
ES2758031T3 (en) 2020-05-04
CY1122382T1 (en) 2021-01-27
BR112012021337A2 (en) 2016-10-25
KR20210124532A (en) 2021-10-14
DK3257500T3 (en) 2019-11-25
ZA201205807B (en) 2016-01-27
JP2017039768A (en) 2017-02-23
US20130045245A1 (en) 2013-02-21
CY1121597T1 (en) 2020-05-29
HK1180248A1 (en) 2013-10-18
JP2016065086A (en) 2016-04-28
PE20130378A1 (en) 2013-03-30
HK1243945B (en) 2020-06-19
EP3017811A1 (en) 2016-05-11
US20160243101A1 (en) 2016-08-25
CY1122529T1 (en) 2021-01-27
EP3246021B1 (en) 2019-11-13
RS59810B1 (en) 2020-02-28
HUE027168T2 (en) 2016-10-28
AU2011220775B2 (en) 2015-09-24
EP2538925A2 (en) 2013-01-02
ES2714363T3 (en) 2019-05-28
HK1243947B (en) 2020-06-19
SI3251660T1 (en) 2019-12-31
US20170202824A1 (en) 2017-07-20
HUE047140T2 (en) 2020-04-28
EP3257500B1 (en) 2019-10-16
CN109602713A (en) 2019-04-12
SMT202000034T1 (en) 2020-03-13
KR20170126016A (en) 2017-11-15
DK3246021T3 (en) 2020-02-03
SG182750A1 (en) 2012-08-30
DK3251660T3 (en) 2019-11-25
ES2758031T8 (en) 2020-08-05
MX2012009244A (en) 2012-08-23
RU2685724C2 (en) 2019-04-23
KR101796300B1 (en) 2017-11-10
SG10201501349VA (en) 2015-04-29
PL3257500T3 (en) 2020-03-31
HRP20190430T8 (en) 2019-06-14
LT3017811T (en) 2019-02-25
SI3017811T1 (en) 2019-04-30
SMT201900650T1 (en) 2020-01-14
PT3257500T (en) 2019-11-26
US9326945B2 (en) 2016-05-03
EP3643301A1 (en) 2020-04-29
PL2538925T3 (en) 2016-06-30
PL3251660T3 (en) 2020-02-28
LT3246021T (en) 2020-02-10
JP6192078B2 (en) 2017-09-06
JP5846647B2 (en) 2016-01-20
JP2017226679A (en) 2017-12-28
HRP20200046T1 (en) 2020-03-20
RS54559B1 (en) 2016-06-30
MX353145B (en) 2017-12-20
RS59593B1 (en) 2020-01-31
EP3017811B1 (en) 2018-12-05
MX364938B (en) 2019-05-15
SI2538925T1 (en) 2016-04-29
HRP20192069T1 (en) 2020-02-07
EP3257500A1 (en) 2017-12-20
LT3257500T (en) 2019-12-10
HRP20190430T1 (en) 2019-05-17
TR201903195T4 (en) 2019-03-21
CA2791171C (en) 2017-08-29
BR112012021337A8 (en) 2016-11-29
PL3017811T3 (en) 2019-06-28
DK2538925T3 (en) 2016-03-14
HRP20192064T1 (en) 2020-02-21
PL3246021T3 (en) 2020-04-30
SMT201600049B (en) 2016-04-29
HUE047139T2 (en) 2020-04-28
CN109602716A (en) 2019-04-12
JP6577980B2 (en) 2019-09-18
PT2538925E (en) 2016-03-18
HK1243946A1 (en) 2018-07-27
PE20210468A1 (en) 2021-03-08
IL251991A0 (en) 2017-06-29
EP3246021A1 (en) 2017-11-22
CY1117434T1 (en) 2017-04-26
IL309564A (en) 2024-02-01
WO2011106478A3 (en) 2012-04-12
SI3257500T1 (en) 2019-12-31
ES2767848T3 (en) 2020-06-18
CA2791171A1 (en) 2011-09-01
CO6640207A2 (en) 2013-03-22
HUE043932T2 (en) 2019-09-30
HK1224216A1 (en) 2017-08-18
KR20130009753A (en) 2013-01-23
US20170202825A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
IN2012DN06587A (en)
MX2012008049A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof.
MX355907B (en) Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels.
MX2015012850A (en) Arginine methyltransferase inhibitors and uses thereof.
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
IL232515A0 (en) Nadph oxidase 4 inhibitors and pharmaceutical compositions containing the same
MX2013010511A (en) Tricyclic gyrase inhibitors.
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2013002660A (en) Heteroarylmethyl amides.
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole
MX2011008645A (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.
UA109793C2 (en) Arylsulphonamide derivatives for the treatment of disorders of the central nervous system
MX356373B (en) Compositions comprising antibacterial agent and tazobactam.
WO2011139253A3 (en) Pharmaceutical compositions comprising ceftibuten
TR201000689A1 (en) Solid dosage forms containing cefprozil.
MX2015000804A (en) Treating ewing's sarcoma and ews-fli1 related disorders.
MX2013007504A (en) Compositions and methods of using crystalline forms of wortmannin analogs.
WO2012023145A3 (en) Prasugrel hydrochloride crystalline particles
EP2061507A4 (en) Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
WO2011151395A3 (en) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
WO2012065100A3 (en) Cxcr4 as a susceptibility locus in juvenile idiopathic arthritis (jia) and methods of use thereof for the treatment and diagnosis of the same
TN2010000391A1 (en) Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
JOP20120346B1 (en) Compounds for adhesion treatment and prevention, compound-related pharmaceutical compositions and methods for the prevention and treatment of adhesions
PH22011000489U3 (en) Solid pharmaceutical herbal compositions